NLSP

USD

NLS Pharmaceutics Ltd. Ordinary Shares

$0.762-0.008 (-1.039%)

السعر في الوقت الحقيقي

Healthcare

التكنولوجيا الحيوية

سويسرا

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق

أساسيات الشركة

إحصاءات التداول

مقاييس السوق

الافتتاح

$0.770

الأعلى

$0.830

الأدنى

$0.760

الحجم

0.00M

أساسيات الشركة

القيمة السوقية

4.0M

الصناعة

التكنولوجيا الحيوية

البلد

Switzerland

إحصاءات التداول

متوسط الحجم

0.07M

البورصة

NCM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $0.76الحالي $0.762الأعلى $43.4

أخبار ذات صلة

٣٠ أكتوبر ٢٠٢٥ · ٠٨:١٥ م

PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and...

عرض المزيد

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

٣٠ أكتوبر ٢٠٢٥ · ١١:٠٠ ص

PR Newswire

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

عرض المزيد

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

٢٩ أكتوبر ٢٠٢٥ · ١٠:٠٠ ص

PR Newswire

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

عرض المزيد

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

٢٩ أكتوبر ٢٠٢٥ · ٠٧:٥٣ ص

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that,...

عرض المزيد

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

٢٧ أكتوبر ٢٠٢٥ · ١١:٠٠ ص

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

عرض المزيد

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

PR Newswire

٢٣ أكتوبر ٢٠٢٥ · ١٠:٠١ ص

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...